{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:17:37Z","timestamp":1761513457099,"version":"build-2065373602"},"reference-count":49,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81070422, 81000223, 81070407"],"award-info":[{"award-number":["81070422, 81000223, 81070407"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013286","name":"Specialized Research Fund for the Doctoral Program of Higher Education","doi-asserted-by":"crossref","award":["20100131110060"],"award-info":[{"award-number":["20100131110060"]}],"id":[{"id":"10.13039\/501100013286","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shandong Technological Development Project","award":["2008GJHZ10202"],"award-info":[{"award-number":["2008GJHZ10202"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.vaccine.2014.04.041","type":"journal-article","created":{"date-parts":[[2014,4,30]],"date-time":"2014-04-30T16:45:18Z","timestamp":1398876318000},"page":"3501-3508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Development and immunological evaluation of HLA-specific chronic myeloid leukemia polyepitope vaccine in Chinese population"],"prefix":"10.1016","volume":"32","author":[{"given":"Wenhao","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingru","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimo","family":"Jian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaolei","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daoxin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.04.041_bib0005","first-page":"107","article-title":"Profile of BCR\u2013ABL transcript levels based on Sokal prognostic score in chronic myeloid leukemia patients treated with imatinib","volume":"45","author":"Ashariati","year":"2013","journal-title":"Acta Med Indones"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0010","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1182\/blood.V85.10.2680.bloodjournal85102680","article-title":"Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules","volume":"85","author":"Bocchia","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0015","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1182\/blood.V87.9.3587.bloodjournal8793587","article-title":"Specific human cellular immunity to bcr\u2013abl oncogene-derived peptides","volume":"87","author":"Bocchia","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0020","doi-asserted-by":"crossref","first-page":"72","DOI":"10.7150\/ijms.7.72","article-title":"WT1 peptide vaccination in combination with imatinib therapy for a patient with CML in the chronic phase","volume":"7","author":"Narita","year":"2010","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0025","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1600-0609.2010.01497.x","article-title":"WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib-treated CML patient","volume":"85","author":"Oji","year":"2010","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0030","doi-asserted-by":"crossref","first-page":"5079","DOI":"10.1158\/1078-0432.CCR-13-0955","article-title":"Generation of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia \u2013 implications for immunotherapy","volume":"19","author":"Weber","year":"2013","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0035","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1080\/10428190400029825","article-title":"Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features","volume":"46","author":"Eisendle","year":"2005","journal-title":"Leukemia Lymphoma"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0040","first-page":"602","article-title":"Construction of genetically modified dendritic cell vaccine expressing bcr\/abl fusion gene and inducing specific cytotoxic T lymphocytes to kill K562 cells in vitro","volume":"28","author":"Wang","year":"2009","journal-title":"Ai zheng=Aizheng=Chin J Cancer"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0045","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1353\/hub.2006.0008","article-title":"Identification of spatial genetic boundaries using a multifractal model in human population genetics","volume":"77","author":"Xue","year":"2005","journal-title":"Hum Biol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0050","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.antiviral.2011.12.005","article-title":"The development of Chinese specific human cytomegalovirus polyepitope recombinant vaccine","volume":"93","author":"Zhao","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0055","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1007\/s00262-002-0328-9","article-title":"Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues","volume":"51","author":"Tsuboi","year":"2002","journal-title":"Cancer Immunol Immunother CII"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/j.1348-0421.2007.tb03940.x","article-title":"WT1 (Wilms\u2019 tumor 1) peptide immunotherapy for renal cell carcinoma","volume":"51","author":"Iiyama","year":"2007","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0065","doi-asserted-by":"crossref","first-page":"3062","DOI":"10.1182\/blood-2005-01-0146","article-title":"Elimination of human leukemia cells in NOD\/SCID mice by WT1-TCR gene-transduced human T cells","volume":"106","author":"Xue","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0070","first-page":"3475","article-title":"Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro","volume":"85","author":"Gu","year":"2005","journal-title":"Zhonghua yi xue za zhi"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0075","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood.V95.1.286","article-title":"HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide","volume":"95","author":"Ohminami","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0080","doi-asserted-by":"crossref","first-page":"8799","DOI":"10.1158\/1078-0432.CCR-05-1314","article-title":"T-cell responses directed against multiple HLA-A*0201-restricted epitopes derived from Wilms\u2019 tumor 1 protein in patients with leukemia and healthy donors: identification, quantification, and characterization","volume":"11","author":"Rezvani","year":"2005","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0085","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ijc.11721","article-title":"WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells","volume":"109","author":"Koesters","year":"2004","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0090","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","article-title":"CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia","volume":"100","author":"Scheibenbogen","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0095","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002510050018","article-title":"Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms\u2019 tumor gene (WT1) product","volume":"51","author":"Oka","year":"2000","journal-title":"Immunogenetics"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0100","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1046\/j.0007-1048.2001.03329.x","article-title":"Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes","volume":"116","author":"Azuma","year":"2002","journal-title":"Brit J Haematol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0105","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/sj.leu.2404354","article-title":"BCR\u2013ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes","volume":"20","author":"Kessler","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0110","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0115","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.4049\/jimmunol.174.12.8210","article-title":"Ex vivo characterization of multiepitopic tumor-specific CD8T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy","volume":"174","author":"Gannage","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0120","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1158\/0008-5472.CAN-06-3737","article-title":"Alternative BCR\/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches","volume":"67","author":"Volpe","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0125","doi-asserted-by":"crossref","first-page":"7476","DOI":"10.1158\/1078-0432.CCR-06-1337","article-title":"Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1","volume":"12","author":"Asemissen","year":"2006","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0130","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1172\/JCI488","article-title":"Cytotoxic T cell response against the chimeric p210 BCR\u2013ABL protein in patients with chronic myelogenous leukemia","volume":"101","author":"Yotnda","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0135","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00262-003-0415-6","article-title":"Identification of new MHC-restriction elements for presentation of the p210(BCR\u2013ABL) fusion region to human cytotoxic T lymphocytes","volume":"52","author":"Sun","year":"2003","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0140","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1038\/sj.leu.2402742","article-title":"Leukemia-associated fusion proteins, dek\u2013can and bcr\u2013abl, represent immunogenic HLA-DR-restricted epitopes recognized by fusion peptide-specific CD4+ T lymphocytes","volume":"16","author":"Makita","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0145","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1182\/blood.V90.1.290.290_290_297","article-title":"HLA-DR1-restricted bcr\u2013abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen-presenting cells exposed to b3a2 containing cell lysates","volume":"90","author":"Mannering","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0150","first-page":"1344","article-title":"Recognition of peptides corresponding to the joining region of p210BCR\u2013ABL protein by human T cells","volume":"9","author":"ten Bosch","year":"1995","journal-title":"Leukemia"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0155","doi-asserted-by":"crossref","first-page":"3522","DOI":"10.1182\/blood.V88.9.3522.bloodjournal8893522","article-title":"Recognition of BCR\u2013ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR\u2013ABL breakpoint peptide","volume":"88","author":"Bosch","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0160","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood.V94.3.1038.415k22_1038_1045","article-title":"A BCR\u2013ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct","volume":"94","author":"ten Bosch","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0165","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00262-002-0362-7","article-title":"The abl\/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl\/bcr can be recognized by both CD4+ and CD8+ T lymphocytes","volume":"52","author":"Wagner","year":"2003","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0170","first-page":"282","article-title":"Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes","volume":"30","author":"Fujiki","year":"2007","journal-title":"J Immunother"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0175","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00262-002-0278-2","article-title":"Prediction of an HLA-DR-binding peptide derived from Wilms\u2019 tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol","volume":"51","author":"Knights","year":"2002","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0180","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/sj.thj.6200220","article-title":"Synthetic peptides derived from the Wilms\u2019 tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells","volume":"4","author":"Muller","year":"2003","journal-title":"Hematol J: Off J Eur Haematol Assoc\/EHA"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0185","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","article-title":"Peptide epitopes from the Wilms\u2019 tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells","volume":"13","author":"May","year":"2007","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0190","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1007\/s00262-005-0071-0","article-title":"Defining MHC class II T helper epitopes for WT1 tumor antigen","volume":"55","author":"Kobayashi","year":"2006","journal-title":"Cancer Immunol Immunother: CII"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0195","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1182\/blood-2005-01-0413","article-title":"Direct recognition and lysis of leukemia cells by WT1-specific CD4+ T lymphocytes in an HLA class II-restricted manner","volume":"106","author":"Guo","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0200","first-page":"5850","article-title":"Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity","volume":"61","author":"Dutoit","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000336","article-title":"The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis","volume":"9","author":"Ariyaratana","year":"2007","journal-title":"Expert Rev Mol Med"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-012-1116-8","article-title":"Biological therapy and the immune system in patients with chronic myeloid leukemia","volume":"96","author":"Rohon","year":"2012","journal-title":"Int J Hematol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0215","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1182\/blood.V95.7.2198","article-title":"Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1","volume":"95","author":"Gao","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/978-1-59745-561-9_13","article-title":"Immunity of lentiviral vector-modified dendritic cells","volume":"542","author":"Han","year":"2009","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0225","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/mt.2009.149","article-title":"Lentiviral vectors transduce proliferating dendritic cell precursors leading to persistent antigen presentation and immunization","volume":"17","author":"Arce","year":"2009","journal-title":"Mol Ther: J Am Soc Gene Ther"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0230","first-page":"103","article-title":"Dendritic cells transfected with lentiviral vector-encoding hTERT peptide augment antitumor T cell response in vitro","volume":"5","author":"Cui","year":"2012","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0235","first-page":"3175","article-title":"Immunogenicity of a p210(BCR\u2013ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro","volume":"62","author":"Sun","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0240","first-page":"97","article-title":"Escape mechanisms in tumor immunity: a year 2000 update","volume":"11","author":"Pawelec","year":"2000","journal-title":"Crit Rev Oncogene"},{"key":"10.1016\/j.vaccine.2014.04.041_bib0245","first-page":"483","article-title":"Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia","volume":"10","author":"Coleman","year":"1996","journal-title":"Leukemia"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14005799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:20:30Z","timestamp":1759400430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14005799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":49,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0264410X14005799"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.041","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2014,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and immunological evaluation of HLA-specific chronic myeloid leukemia polyepitope vaccine in Chinese population","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.04.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}